New Data from the KARDIA-2 Phase 2 Study of Zilebesiran and the APOLLO-B Phase 3 and APOLLO-OLE Studies of Patisiran Presented at the European Society of Cardiology (ESC) Congress 2024

01 Sep, 2024 New Data from the KARDIA-2 Phase 2 Study of Zilebesiran and the APOLLO-B Phase 3 and APOLLO-OLE Studies of Patisiran Presented at the European Society of Cardiology (ESC) Congress 2024

Findings from a subgroup analysis of the KARDIA-2 Phase 2 study of zilebesiran, in development for the treatment of hypertension, and new data from post-hoc analyses of the APOLLO-B Phase 3 and APOLLO-OLE studies of patisiran in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) were presented at the European Society of Cardiology Congress (ESC) 2024.

Saxena, et al. “Subgroup Results from KARDIA-2: Impact of Demographic and Baseline Disease Characteristics on Zilebesiran Response in Patients with Hypertension Uncontrolled by a Standard Oral Antihypertensive”

Lairez, et al. “Long-term Effects of Patisiran on Survival and Cardiac Parameters in Patients with Transthyretin-Mediated Cardiac Amyloidosis: Post-hoc Analyses of APOLLO-B and Cardiac Subpopulation of APOLLO-OLE”